T
Tomoko Ichisaka
Researcher at Kyoto University
Publications - 30
Citations - 38586
Tomoko Ichisaka is an academic researcher from Kyoto University. The author has contributed to research in topics: Induced pluripotent stem cell & Embryonic stem cell. The author has an hindex of 23, co-authored 29 publications receiving 35135 citations.
Papers
More filters
Journal ArticleDOI
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Kazutoshi Takahashi,Koji Tanabe,Mari Ohnuki,Megumi Narita,Tomoko Ichisaka,Kiichiro Tomoda,Shinya Yamanaka +6 more
TL;DR: It is demonstrated that iPS cells can be generated from adult human fibroblasts with the same four factors: Oct3/4, Sox2, Klf4, and c-Myc.
Journal ArticleDOI
Generation of germline-competent induced pluripotent stem cells
TL;DR: iPS cells competent for germline chimaeras can be obtained from fibroblasts, but retroviral introduction of c-Myc should be avoided for clinical application.
Journal ArticleDOI
Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors
Kazutoshi Takahashi,Koji Tanabe,Mari Ohnuki,Megumi Narita,Tomoko Ichisaka,Kiichiro Tomoda,Shinya Yamanaka +6 more
TL;DR: This work generated induced pluripotent stem cells capable of germline transmission from murine somatic cells by transd, and demonstrated the ability of these cells to reprogram into patient-specific and disease-specific stem cells.
Journal ArticleDOI
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts
Masato Nakagawa,Michiyo Koyanagi,Koji Tanabe,Kazutoshi Takahashi,Tomoko Ichisaka,Takashi Aoi,Keisuke Okita,Yuji Mochiduki,Nanako Takizawa,Shinya Yamanaka +9 more
TL;DR: A modified protocol for the generation of iPS cells that does not require the Myc retrovirus is described and, with this protocol, significantly fewer non-iPS background cells are obtained, and theiPS cells generated were consistently of high quality.
Journal ArticleDOI
Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors
TL;DR: The production of virus-free iPS cells, albeit from embryonic fibroblasts, addresses a critical safety concern for potential use of i PS cells in regenerative medicine.